Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Diseases × Drug Evaluation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Breast Neoplasms 3 Lymphoma, Non-Hodgkin 2 Colorectal Neoplasms 2 Carcinoma, Basal Cell 2 Basal Cell Nevus Syndrome 2 Upper Tract Urothelial Carcinomas 1 Thrombocythemia, Essential 1 Solid Tumors 1 Serous Ovarian Cancer 1 Recurrence 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Polycythemia Vera 1 Lymphedema 1 Liver Neoplasms 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Hypogonadism 1 Glioma 1 Fatigue Syndrome, Chronic 1 Fallopian Tube Neoplasms 1 Eunuchism 1 Carcinoma, Ovarian Epithelial 1 Breast Diseases 1 Amyloidosis 1 Adenoma 1

Interventions

palbociclib 6 Letrozole 6 Docetaxel 6 Anastrozole 6 exemestane 5 Trastuzumab 5 Fulvestrant 5 ribociclib 4 entinostat 4 abemaciclib 4 Cyclophosphamide 4 pyrotinib 3 Doxorubicin 3 Sodium Chloride 2 Paclitaxel 2 Lapatinib 2 Gonadotropin-Releasing Hormone 2 Exercise 2 Everolimus 2 Epirubicin 2 Capecitabine 2 Botulinum Toxins, Type A 2 AZD9833 2 tucatinib 1 sacubitril and valsartan sodium hydrate drug combination 1 pertuzumab 1 pembrolizumab 1 pegfilgrastim 1 ipatasertib 1 gadoterate meglumine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡